Neurogene prices $125 million public offering at $30.00 per share

Neurogene Inc. finalized terms for a public offering on June 30, 2026, according to a prospectus supplement filed with the SEC. The company is offering 3,500,000 shares of common stock and, in lieu of shares to certain investors that so choose, pre-funded warrants to purchase 666,666 shares of common stock.¹ The public offering price for each share of common stock is $30.00.¹

The filing shows total public offering proceeds of $124,999,979 before underwriting discounts and commissions of $7,499,999, leaving proceeds before expenses to Neurogene of $117,499,980.¹ The underwriters were granted a 30-day option to purchase up to an additional 624,999 shares, which if exercised in full would bring total underwriting discounts and commissions to approximately $8.6 million and total proceeds before expenses to approximately $135.1 million.¹ Delivery of the shares and pre-funded warrants is expected on or about July 2, 2026.¹

Neurogene estimated net proceeds of approximately $117.2 million, which it plans to use along with existing cash to fund ongoing clinical development of NGN-401, pre-commercial activities for the program, and general corporate purposes.¹ The company said the net proceeds together with existing cash should fund operations into the third quarter of 2028.¹

Neurogene's lead program targets Rett syndrome. Its ongoing registrational trial, titled "Embolden," is described as a single-arm, open-label, baseline-controlled study evaluating a 1E15 vg dose of NGN-401 in females with the disease.¹ On June 8, 2026, the company announced it had completed dosing in Embolden, with 25 participants receiving the 1E15 vg dose.¹